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Short Communication
A chlorambucil-anti-CEA conjugate cytotoxic for human
colon adenocarcinoma cells in vitro
L.G. Bemierl, M. Page1, R.C. Gaudreault & L.P. Joly
'Department ofBiochemistry and School ofPharmacy, Universite Laval, Quebec, Canada.
The use of chlorambucil (CBL) for the chemothera-
peutic treatment of cancer is often limited because
of undesirable side effects due to its lack of
specificity for cancer cells. Systemic effects such as
renal toxicity, marrow aplasia, pulmonary fibrosis
and gastrointestinal disorders may be eliminated or
greatly reduced by increasing the specificity of the
drug towards tumour cells. Carcinoembryonic
antigen (CEA), an oncofoetal protein produced by
some human cancer cells (Gold & Friedman, 1965),
is extensively used as a clinical cancer marker for
the follow-up of treated patients. We have already
reported that this protein could be a target for
daunorubicin-anti-CEA conjugates (Belles-Isles &
Page, 1981; Page et al., 1981).
Many authors have already described a method
to adsorb chlorambucil to antitumour antibodies
(Blakeslee & Kennedy,1974; Guclu et al., 1976), but
in the previous applications of chlorambucil-
antibody conjugates, a certain percentage of the
reported activity could have been due to the
presence of a non-covalently bound aggregate of
the drug (Blakeslee et al., 1975). The other method
described for the covalent coupling of CBL (Tai et
al., 1979) could lead to polymerisation of the
carrier and needed a 2h incubation in an aqueous
solution.
We present here a new method for the covalent
binding of chlorambucil which allows a rapid
coupling to proteins without any significant
polymerisation. This was obtained using the
isocyanate derivative of chlorambucil: 3-{4-[bis(2-
chloroethyl)amino]phenyl}propyl-1-isocyanate. The
conjugate was separated from the remaining free
drug by gel filtration on Sephadex G-25 (Pharmacia
Fine Chemicals) and the drug:protein ratio was
determined by a photofluorometric method to assay
the alkylating activity of CBL (Bernier et al., 1983).
This ratio could be varied by mixing various
proportions of the drug derivative and of the
antibody; in the assay conditions reported a ratio
of 25 moles of drug per mole of antibody was used.
The cytotoxic effects of chlorambucil-anti-CEA
conjugates on LoVo cells (CEA producing human
colon carcinoma cells) were evaluated by the
inhibition of colony formation as already described
(Emond & Page, 1982). Figure 1 illustrates that for
any concentration of drug used, the highest
inhibition of colony formation was obtained with
the covalent drug-antibody conjugate. Also the
antibodies were neither cytolytic nor cytostatic for
these cells in vitro. The concentration required to
obtain a 50% inhibition of colony formation (ID
50) was much lower for the conjugate than for the
free drug, the physical mixture of both agents or
chlorambucil conjugated to non-specific antibodies
(anti-alphafoetoprotein). Experiments on non-CEA
producing cells (CCL6; human amnions) showed
the specificity of the CBL-anti-CEA conjugate for
CEA producing cell lines (Table I).
The contact period study (Figure 2) shows that a
rapid binding of the CBL-anti-CEA conjugate
allows a much higher pharmacological activity
when compared to equimolar concentrations of the
free drug.
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Figure 1 Inhibition of colony formation: 2500 LoVo
cells were treated with various concentrations of
chlorambucil (0); anti-CEA immunoglobulins (0);
drug and antibody mixture (El) and the conjugate
(-).
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Table I Effect of free or bound chlorambucil
on CEA (+) (LoVo) and CEA (-) (CCL6)
cells, ID 50 is the concentration (in ygml-1)
required to obtain a 50% inhibition of colony
formation.
ID 50 (ugml m1)
LoVo cells CCL6 cells
Treatment CEA(+) CEA(-)
Chlorambucil 5,0 3,0
CBL-anti-CEA 0,3 3,0
conjugate
CBL-anti-AFP 6,0 4,0
conjugate
CBL+ anti-CEA 5,8 5,0
anti-CEA alone N.C. N.C.
aN.C.: Not cytotoxic.
These results represent the first application
reported to date on the use of an isocyanate
function for the covalent binding of alkylating
drugs with specific antibodies. The cytotoxicity of
the drug-antibody conjugate over a short-term
exposure shows the avidity of the conjugate for the
tumour cells. Although CEA is not tumour specific,
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Figure 2 Contact period treatment: 2500 LoVo cells
were treated with 10 igml ' of free or conjugated
drug for short periods, washed and reincubated for 6-
9 days in fresh RPMI-1640 medium. Free
chlorambucil (El) and drug-antibody conjugate (U).
its concentration may be greatly increased in
gastrointestinal, lung and pancreas carcinomas and
in various malignancies. Antibodies against CEA
may therefore be useful carriers for cytotoxic
compounds, thereby achieving a selective
accumulation of the drug at its desired site of
action.
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